Uterine artery embolisation (UAE) has been widely described internationally, however there is a paucity of data reported from Australia.
To conduct a local audit on the efficacy and safety of UAE treating symptomatic fibroids and adenomyosis.
Clinical data of 76 consecutive UAEs were reviewed. Degree of fibroid‐related symptoms before embolisation and at follow‐up visits were compared. Procedural and subsequent complications were recorded. Uterine and fibroid volumes were measured on MRI at baseline and six months post‐UAE.
Seventy‐six UAEs were performed in 75 women. Fifty‐nine women had follow‐up duration of more than six months, and one woman was lost to follow‐up. Clinical success was 93% overall (n = 59) and 96% for menorrhagia (n = 49). For dysmenorrhoea (n = 36), 89% of women had at least some improvement, 75% had significant improvement and 56% had resolution of pain. For urinary symptoms (n = 32), 97% of women had at least some improvement and 50% had resolution of all urinary symptoms. Adenomyosis was found in 17 (29%) women treated. The primary success rate was 96%, and secondary success rate (after repeat UAE) was 100%. MRI showed 50% uterine volume reduction and 60% dominant fibroid volume reduction. There were no significant procedural‐related acute complications. There were three possible cases of endometritis, two managed conservatively and one required hysterectomy.
This audit, based on local Australian experience, has confirmed that UAE is a safe and highly effective treatment for women with symptomatic fibroids and/or adenomyosis.